Core Insights - IQVIA Holdings Inc. is a healthcare research services provider valued at $28 billion, offering analytics, technology solutions, and clinical research services to the life sciences industry [1] Performance Overview - IQV's shares have underperformed the broader market, declining 11.4% over the past year, while the S&P 500 Index has increased by nearly 12.3% [2] - In 2026, IQV's stock fell 24.1%, contrasting with the marginal rise of the S&P 500 on a year-to-date basis [2] Comparative Analysis - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 9.1% over the past year, IQV's performance has been notably weaker, with the ETF's 1.9% returns year-to-date outpacing IQV's double-digit losses [3] Financial Performance - IQV's underperformance is attributed to margin compression and concerns regarding the sustainability of gains, despite acquisitions that expanded capabilities [6] - In Q4, IQV reported an adjusted EPS of $3.42, exceeding Wall Street expectations of $3.40, with revenue of $4.4 billion surpassing forecasts of $4.2 billion [7] - For the full year, IQV expects adjusted EPS in the range of $12.55 to $12.85 and revenue between $17.2 billion and $17.4 billion [7] Future Projections - Analysts project IQV's EPS to grow by 6.9% to $11.56 on a diluted basis for fiscal 2026 [8] - The company's earnings surprise history is mixed, with three out of the last four quarters beating consensus estimates [8] - Among 22 analysts covering IQV stock, the consensus rating is a "Strong Buy," supported by 16 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [8]

Core Insights - IQVIA Holdings Inc. is valued at $37.6 billion and provides healthcare research services, including analytics, technology solutions, and clinical research to the life sciences industry, aimed at improving healthcare outcomes for patients [1] Performance Overview - Over the past year, IQV shares have gained 12.2%, underperforming the S&P 500 Index, which increased by nearly 13.7% [2] - In 2025, IQV's stock rose 10%, while the S&P 500 saw a 13.4% rise on a year-to-date basis [2] - Compared to the Health Care Select Sector SPDR Fund (XLV), which gained about 7% over the past year, IQV's performance is relatively better, although the ETF's 10.3% year-to-date returns outshine IQV's gains [3] Financial Results - For Q3, IQV reported an adjusted EPS of $3, exceeding Wall Street expectations of $2.96, and revenue of $4.10 billion, beating forecasts of $4.07 billion [4] - The company expects full-year adjusted EPS to be in the range of $11.85 to $11.95 and revenue between $16.2 billion and $16.3 billion [4] Analyst Expectations - Analysts project IQV's EPS to grow by 5.1% to $10.77 for the current fiscal year ending in December [5] - Among 22 analysts covering IQV, the consensus rating is a "Strong Buy," with 16 "Strong Buy" ratings, one "Moderate Buy," and five "Holds" [5] - A month ago, the bullish sentiment increased, with 15 analysts suggesting a "Strong Buy" [6] Price Targets - BMO Capital initiated coverage of IQV with an "Outperform" rating and a price target of $260, indicating a potential upside of 20.3% from current levels [6] - The mean price target is $244.38, representing a 13.1% premium to current prices, while the highest price target of $265 suggests an upside potential of 22.6% [6]